Suzhou Connect Biopharma reported a successful Phase I study of CBP-307, its lead molecule and a drug candidate for several autoimmune diseases. The single ascending dose study assessed the tolerability, pharmacokinetics and pharmacodynamics of CBP-307. According to Connect, CBP-307 exhibited "highly potent" immune modulation activity at each level in a dose-dependent manner. The study was conducted by Connect's Australian subsidiary in Melbourne.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
